A new mechanism of resistance of HIV-2 to integrase inhibitors: a 5 amino-acids insertion in the integrase C-terminal domain.

Background Integrase strand-transfer inhibitors (INSTI) are crucial for treatment of HIV-2 infection, due to limited available therapeutic options. Recently, bictegravir has been approved for HIV-1-infected patients but no data are currently available for HIV-2. Methods We assessed phenotypic susceptibility to the five INSTI (bictegravir, cabotegravir, dolutegravir, elvitegravir and raltegravir) of 12 HIV-2 clinical isolates obtained from two antiretroviral-naïve and 10 antiretroviral-experienced patients at virological failure of an INSTI-based regimen. 50% Inhibitory Concentrations (IC50) were determined. Phenotypic Inhibitory Quotients were determined after measurement of trough INSTI plasma concentrations. Results Wild-type viruses were susceptible to the five INSTI with IC50 in the low nanomolar range. Bictegravir had lower IC50 than other INSTIs on HIV-2 isolates bearing major resistance-associated mutations (RAM, i.e. codons 143, 148 and 155). We identified a new INSTI-resistance profile, a 5-amino-acids insertion at codon 231 of HIV-2 integrase (231INS) in six patients at virological failure of a raltegravir-based regimen. Those patients had adequate raltegravir concentrations but harboured multi-resistant viruses with low genotypic susceptibility score (median=1.5). This insertion rendered isolates highly resistant to raltegravir and elvitegravir, and moderately resistant to dolutegravir and cabotegravir. Regarding bictegravir, two isolates remained susceptible and two had a slight increase in IC50 (3- to 5-fold-change). Conclusions Our results confirm the potency of integrase inhibitors on wild-type integrase HIV-2 clinical isolates. In addition, we identified a new INSTI resistance pathway, 231INS, selected in highly antiretroviral-experienced patients with multi-resistant HIV-2 viruses. This highlights the need of a close follow-up of such patients initiating an INSTI-based regimen.

[1]  G. Gottlieb,et al.  A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  G. Gottlieb,et al.  In Vitro Antiviral Activity of Cabotegravir against HIV-2 , 2018, Antimicrobial Agents and Chemotherapy.

[3]  G. Gottlieb,et al.  90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. , 2018, The lancet. HIV.

[4]  C. Charpentier,et al.  Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads. , 2018, Journal of virological methods.

[5]  S. Hughes,et al.  Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants , 2018, Retrovirology.

[6]  T. Seki,et al.  Novel secondary mutations C56S and G149A confer resistance to HIV‐1 integrase strand transfer inhibitors , 2018, Antiviral research.

[7]  C. Charpentier,et al.  First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2) , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  D. Podzamczer,et al.  Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial , 2017, The Lancet.

[9]  M. Wainberg,et al.  Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1 , 2017, Antimicrobial Agents and Chemotherapy.

[10]  K. White,et al.  Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile , 2016, Antimicrobial Agents and Chemotherapy.

[11]  S. Khoo,et al.  Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. , 2016, The Journal of antimicrobial chemotherapy.

[12]  G. Gottlieb,et al.  Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors , 2015, Journal of Virology.

[13]  J. Eron,et al.  Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. , 2015, The Lancet. Infectious diseases.

[14]  C. Charpentier,et al.  HIV-2EU-Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  C. Charpentier,et al.  Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  G. Gottlieb,et al.  In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2 , 2015, Retrovirology.

[17]  E. Garvey,et al.  Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection , 2014, Antimicrobial Agents and Chemotherapy.

[18]  C. Rouzioux,et al.  New Sensitive One-Step Real-Time Duplex PCR Method for Group A and B HIV-2 RNA Load , 2014, Journal of Clinical Microbiology.

[19]  C. Charpentier,et al.  Genotypic resistance profiles of HIV-2-treated patients in West Africa , 2014, AIDS.

[20]  F. Antunes,et al.  Baseline Susceptibility of Primary HIV-2 to Entry Inhibitors , 2012, Antiviral therapy.

[21]  G. Gottlieb,et al.  Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance , 2011, AIDS.

[22]  C. Charpentier,et al.  G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not , 2011, Retrovirology.

[23]  C. Charpentier,et al.  In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572 , 2010, AIDS.

[24]  G. Gottlieb,et al.  Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  F. Brun-Vézinet,et al.  HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. , 2008, The Journal of antimicrobial chemotherapy.

[26]  F. Brun-Vézinet,et al.  In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors , 2008, Antimicrobial Agents and Chemotherapy.

[27]  B. Jung,et al.  Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. , 2007, Biomedical chromatography : BMC.

[28]  M. Kozal,et al.  Natural Polymorphism of the HIV-1 Integrase Gene and Mutations associated with Integrase Inhibitor Resistance , 2007, Antiviral therapy.

[29]  C. Kovacs,et al.  Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals , 2006, Journal of acquired immune deficiency syndromes.

[30]  F. Brun-Vézinet,et al.  High frequency of selection of K65R and Q151M mutations in HIV‐2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen , 2004, Journal of medical virology.

[31]  W. Heneine,et al.  Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis , 2004, Antiviral therapy.

[32]  A. Vandamme,et al.  A Genotypic Drug Resistance Interpretation Algorithm that Significantly Predicts Therapy Response in HIV-1-Infected Patients , 2001, Antiviral therapy.

[33]  V. Calvez,et al.  Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors , 2001, Antimicrobial Agents and Chemotherapy.

[34]  R. Plasterk,et al.  Refined solution structure of the c‐terminal DNA‐binding domain of human immunovirus‐1 integrase , 1999, Proteins.

[35]  D. Stuart,et al.  A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance , 1999, Antimicrobial Agents and Chemotherapy.

[36]  D. Katzenstein,et al.  A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. , 1998, The Journal of clinical investigation.

[37]  R. Plasterk,et al.  Structure-Based Mutational Analysis of the C-Terminal DNA-Binding Domain of Human Immunodeficiency Virus Type 1 Integrase: Critical Residues for Protein Oligomerization and DNA Binding , 1998, Journal of Virology.

[38]  F. Brun-Vézinet,et al.  HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. , 1992, Journal of virological methods.

[39]  R. Cheynier,et al.  LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur. , 1991, Science.

[40]  F. Brun-Vézinet,et al.  Isolation of a new human retrovirus from West African patients with AIDS. , 1986, Science.